The Claim
In adults with overweight or obesity and cardiovascular disease but without diabetes, the kidney benefits observed with once-weekly semaglutide 2.4 mg are likely independent of changes in HbA1c and blood pressure, as exploratory analyses indicate minimal correlation between estimated glomerular filtration rate (eGFR) change and within-person fluctuations in these parameters, suggesting additional mechanisms beyond glycemic or hemodynamic control contribute to renal outcomes.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
The kidney benefits from taking a weekly semaglutide shot for weight and heart health probably aren't just because it lowers blood sugar or blood pressure — there might be other ways it's helping the kidneys.
See the scientific wording
The kidney benefits of once-weekly semaglutide 2.4 mg in adults with overweight or obesity and cardiovascular disease without diabetes are likely independent of changes in HbA1c and blood pressure, as exploratory analyses showed little correlation between eGFR change and within-person changes in these parameters, suggesting additional mechanisms beyond glycemic or hemodynamic control.
What the research says
1 studyStudy: Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial
The study looked at a weight-loss drug called semaglutide and found it helped protect the kidneys in people with obesity and heart disease. The claim says these kidney benefits aren’t just because of better blood sugar or blood pressure, and the study doesn’t disagree.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.